SPOTLIGHT: CytRx reviews toxicology data

Last week the FDA halted CytRx Phase II trial of a drug for Lou Gehrig's disease in order to analyze results from animal studies of arimoclomol. The FDA has clarified its decision and CytRx is now analyzing data from the previously completed toxicology study to prepare a response to the issues cited by the FDA. Release

Suggested Articles

Bausch Health is paying $10 million upfront for the option to acquire Allegro Ophthalmics’ eye disease assets, with a promise of $40 million to come.

Anthony Coyle, Ph.D., has signed up to run Repertoire Immune Medicines’ R&D.

The IPO haul will set Kronos up to start a registrational phase 2/3 trial of a first-line AML drug licensed from Bischofberger's former employer.